Alphawave Semi and InnoLight Collaborate to Demonstrate Low Latency Linear Pluggable Optics with PCIe 6.0® Subsystem Solution for High-Performance AI Infrastructure at OFC 2024
Alphawave Semi (LSE: AWE), a global leader in high-speed connectivity and compute solutions for the world’s technology infrastructure, today announced its collaboration with InnoLight Technology, the leader in data center optics, to bring a low power, low latency linear pluggable optics (LPO) demonstration to OFC 2024. Operating at 64 Gbps per lane, this demonstration showcases Alphawave Semi’s PCIe 6.0® subsystem (Controller + PHY) with InnoLight’s LPO OSFP optics, breaking down barriers to disaggregated networking and enabling connectivity at the datacenter scale. By delivering a complete PCIe 6.0 subsystem featuring Alphawave Semi’s controller IP matched with its industry-leading proven PAM4 SerDes PHY and by collaborating with InnoLight as an industry-leading optics supplier, Alphawave Semi is fostering an ecosystem for accelerating the deployment of optical connectivity and memory coherency solutions, which are essential for scaling AI workloads in next-generation data center infrastructure.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240325631180/en/
Low Latency Linear Pluggable Optics with PCIe 6.0® Subsystem for High-Performance AI Infrastructure (Graphic: Business Wire)
Osa Mok, Chief Marketing Officer at InnoLight, said, “We are pleased with the collaboration between Alphawave Semi and InnoLight, which demonstrates PCIe 6.0 optical connectivity that offers both low power consumption and low latency, tailored to meet the demanding requirements of high-bandwidth and high-density AI networks. Alphawave Semi’s PAM4 DSP physical layer technology, leveraged with InnoLight’s LPO OSFP, empowers hyperscalers to implement next-generation disaggregated, composable networks.“
Tony Chan Carusone, CTO at Alphawave Semi, said, “We see our collaboration with InnoLight as a significant driver for accelerating the adoption of PCIe technology over optics. The combination of InnoLight’s market-leading optical solution with Alphawave Semi’s robust DSP technology showcases how PCIe technology over optics can enable our customers to massively scale connectivity for their compute and data processing AI workloads.”
Live Demonstration at OFC Exhibit Hall, InnoLight Booth 2625
Attendees can experience a live demonstration of low power, low latency linear pluggable optics (LPO). Operating at 64 Gbps per lane, it showcases Alphawave Semi’s PCIe 6.0 subsystem (Controller + PHY) with InnoLight’s LPO OSFP optics.
More on Alphawave Semi’s PCIe Portfolio: Alphawave Semi’s PCI-Express and CXL Solution
The Alphawave Semi PCIe Controller + PHY subsystem is an extremely power-efficient, low-latency, and highly reliable interface IP, having been built off the industry’s most successful PAM4 SerDes IP. It is available on the most advanced technology nodes. In AI and high-performance computing (HPC) systems where memory performance is key, the Alphawave Semi PCIe 6.0 Subsystem can be expanded to support CXL 3.0 with a PCIe and CXL Controller and enable memory coherency at the data center level.
InnoLight offers a wide range of low power, low latency 400G, 800G, and 1.6T LPO solutions for AI workloads at data center scale, with a silicon photonics platform, with expected capabilities to support PCIe Gen 6 and beyond optical connectivity. InnoLight is also a founding member of LPO-MSA (www.lpo-msa.org), and is actively working with the industry ecosystem to promote wide adoption of LPO solutions for AI networking and computing applications.
PCI-SIG®, PCI Express®, and PCIe ® are registered trademarks and/or service marks of PCI-SIG
About Alphawave Semi
Alphawave Semi is a global leader in high-speed connectivity and compute silicon for the world's technology infrastructure. Faced with the exponential growth of data, Alphawave Semi's technology services a critical need: enabling data to travel faster, more reliably, and with higher performance at lower power. We are a vertically integrated semiconductor company, and our IP, custom silicon, and connectivity products are deployed by global tier-one customers in data centers, compute, networking, AI, 5G, autonomous vehicles, and storage. Founded in 2017 by an expert technical team with a proven track record in licensing semiconductor IP, our mission is to accelerate the critical data infrastructure at the heart of our digital world. To find out more about Alphawave Semi, visit: awavesemi.com.
Alphawave Semi and the Alphawave Semi logo are trademarks of Alphawave IP Group plc. All rights reserved.
About InnoLight Technology
InnoLight is a world leader in providing a wide range of high-speed optical solutions for optical communication networking, especially for AI and Data Center applications, with global footprints in California, Singapore, Thailand, Taiwan, and Suzhou China. For more information, please visit www.innolight.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240325631180/en/
Contact information
Gravitate PR for Alphawave Semi
alphawave@gravitatepr.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 14:00:00 EET | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreement were not disclosed. “This new agreement builds upon our recent co-development collaboration with Acepodia, which has focused on the evaluation and selection
Blockstream Capital Partners Announces Strategic Acquisition of Derivatives Trading Team from Numeus Group, Leveraging Strategic Partnership with Komainu9.1.2026 12:08:00 EET | Press release
Blockstream Capital Partners (“BCP”) today announced that it has entered into a strategic agreement to acquire a division within Numeus Group’s digital asset trading and investment business. The transaction includes the absorption of select Bitcoin focused trading strategies with a focus on yield generation as well as a ten person derivatives trading team led by Chief Investment Officer Deepak Gulati, a specialist in volatility and derivatives markets. Deepak Gulati, appointed Co-Chief Investment Officer of Blockstream Capital Management alongside Rodrigo Rodriguez, previously served as Global Head of Proprietary Trading at JPMorgan, before founding Argentiere Capital, a multibillion-dollar volatility-focused hedge fund. With a thesis that derivatives would drive Bitcoin and digital asset market maturity, he co-founded Numeus Group in 2021 to develop institutional-grade trading, risk management and market-structure capabilities. Komainu, an existing BCP strategic investment, has played
Autel Unveils Strategic Shift at CES 2026: Building the AI-Powered Infrastructure of Future Cities9.1.2026 11:44:00 EET | Press release
At the Consumer Electronics Show (CES), Autel Energy is presenting its latest AI-driven smart hardware and software systems for the future of intelligent urban operations. This year’s showcase highlights Autel’s shift from AI concept validation to scenario-based engineering deployment, emphasizing closed-loop execution across real-world infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260101511436/en/ Autel Energy New Product Debut at CES 2026 Focusing on two key domains — Smart Energy and Smart Inspection — the company is unveiling a range of new products. In Smart Energy, Autel is introducing V2G (Vehicle-to-Grid) AC charger for homes and DC charging solution for fleets, strengthening its multi-tier energy touchpoint strategy from households to commercial operations. Live demonstrations at the booth will feature a smart charging robot showcasing automated plug-in capabilities. In Smart Inspection, Autel will
Allianz and Anthropic Forge Global Partnership to Advance Responsible AI in Insurance9.1.2026 11:00:00 EET | Press release
Allianz SE and Anthropic today announced a global partnership to accelerate the adoption of responsible Artificial Intelligence (AI) at Allianz. The collaboration centers on three transformative projects within Allianz Group designed to empower Allianz employees and accelerate operations, while setting new benchmarks for accuracy. “With this partnership, Allianz is taking a decisive step to address critical AI challenges in insurance. Anthropic’s focus on safety and transparency complements our strong dedication to customer excellence and stakeholder trust. Together, we are building solutions that prioritize what matters most to our customers while setting new standards for innovation and resilience,” said Oliver Bäte, CEO of Allianz SE. “Insurance is an industry where the stakes of using AI are particularly high: the decisions can affect millions of people. Allianz and Anthropic both take that very seriously, and we look forward to working together to make insurance better for those w
MRM Health Secures FDA IND Clearance to Launch its Phase 2b Trial of MH002 in Mild-to-Moderate Ulcerative Colitis9.1.2026 08:00:00 EET | Press release
MRM Health NV, a clinical-stage biopharmaceutical company pioneering microbiome-based therapeutics for inflammatory diseases and immune-oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted clearance of its Investigational New Drug (IND) application for its lead program MH002. This enables the initiation of the STARFISH-UC Phase 2b clinical trial in patients with mild-to-moderate ulcerative colitis, marking a significant step forward in the development of next-generation therapies for inflammatory bowel diseases (IBD). About the STARFISH-UC Phase 2b Trial The STARFISH-UC trial is a randomized, double-blind, placebo-controlled study designed to confirm the promising efficacy signals and favorable safety profile previously observed in MH002’s Phase 2a studies. MH002, a rationally designed live microbial consortium, is the most advanced Live Biotherapeutic Product (LBP) of its kind, targeting disease-specific mechanisms through a synergistic combination of
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom